权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Development of a Four-Class, Molecular Subtyping Diagnostic for HPV-negative Head and Neck Cancer

开发 HPV 阴性头颈癌的四类分子亚型诊断方法

基本信息

批准号：
10216187
负责人：
David N Hayes
金额：
$ 49.78万
依托单位：
WASHINGTON UNIVERSITY
依托单位国家：
美国
项目类别：
财政年份：
2017
资助国家：
美国
起止时间：
2017-08-01 至 2023-07-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/10216187
关键词：
Address Anatomy Biological Biological Assay Cells Cessation of life Characteristics Clinic Clinical Clinical Data Clinical Management Clinical Markers Collaborations Combined Modality Therapy Data Data Set Decision Making Development Diagnostic Diagnostic radiologic examination Etiology Exhibits Formalin Gene Expression Genes Genomics Goals Head and Neck Cancer Head and Neck Squamous Cell Carcinoma Histologic Human Papillomavirus Immune response Incidence Individual Industry Collaboration Knowledge Laboratories Laryngeal Squamous Cell Carcinoma Larynx Lymph Node Dissections Malignant Neoplasms Malignant neoplasm of larynx Manufacturer Name Marketing Mesenchymal Modality Molecular Mutation Neck Dissection Neoplasm Metastasis Nodal North Carolina Operative Surgical Procedures Oral Stage Oropharyngeal Outcome Paraffin Embedding Patient Care Patient-Focused Outcomes Patients Pharmacologic Substance Pharyngeal structure Population Production Prognosis Public Health Radiation Radiation therapy Research Risk Risk Management Sampling Selection for Treatments Stratification The Cancer Genome Atlas Therapeutic Tissue Embedding Tobacco Tobacco use Translating Treatment Failure Tumor Subtype Tumor stage United States Work base cancer care cancer genomics cancer subtypes chemotherapy clinically relevant common treatment design detection assay diagnostic assay drug development gene panel genetic signature genomic biomarker high risk hypopharynx improved in-vitro diagnostics interest malignant mouth neoplasm malignant oropharynx neoplasm molecular marker molecular modeling molecular subtypes mouth squamous cell carcinoma novel personalized diagnostics personalized medicine predicting response predictive test prognostic prognostic assays radiation resistance radiation response risk stratification socioeconomics statistics support tools transcriptome transcriptome sequencing treatment responders treatment response treatment strategy tumor tumor registry

项目摘要

Abstract: Head and neck squamous cell carcinoma (HNSCC), including cancers of the oral cavity, pharynx, and larynx, is the sixth most common cancer worldwide worldwide. In the United States, approximately 60,000 new cases of HNSCC and 12,000 deaths are projected for 2015. A growing body of evidence demonstrates increasing incidence of oropharyngeal cancers, including a subset of human papillomavirus (HPV) associated tumors that demonstrate better prognosis. Despite the recent research interest in HPV-positive HNSCC, HPV-negative tobacco-associated cases continue to comprise the vast majority of HNSCC. Particularly in our state of North Carolina, where the population is more racially and socioeconomically diverse and where tobacco use remains high, HPV-negative HNSCC remains a significant public health problem. Oncologic outcomes for HPV-negative HNSCC remain poor and have not improved in the last 50 years, and there is a need to identify novel, personalized diagnostics and treatment strategies for patients with HPV-negative HNSCC. Four intrinsic HNSCC gene expression subtypes (basal (BA), classical (CL), mesenchymal (MS) and atypical (AT)) have been described, and provide an opportunity to inform patient management. These subtypes exhibit distinct differences in cell of origin, tumor drivers, proliferation, prognosis, and host immune response. In this application, we intend to develop and validate a clinic-ready diagnostic for HPV-negative HNSCC that includes both prognostic and predictive applications. While several therapeutic options exist for HNSCC including surgery, radiation therapy, and, chemotherapy, treatment selection remains empiric. With the exception of HPV status in oropharyngeal cancer, the molecular characteristics of individual tumors are generally not taken into account when deciding on treatment. This academic/industry collaboration will provide prognostic information based on biologic gene expression subtypes to guide decision-making for HPV-negative HNSCC, such as application of more aggressive surgery or radiation therapy based on tumor characteristics. We hypothesize that development efforts as described in this application will lead to a clinic-ready subtyping diagnostic, that combined with other mutation and clinical data, will provide both prognostic and predictive applications to guide the management of HNSCC.

文摘: